Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Nonablative hematopoietic cell transplantation (HCT) is becoming a preferred treatment for those recipients in whom the potential toxicity risk of standard ablative allogeneic therapy may be unacceptable. Graft-versus-malignancy effects may be generated against epithelial malignancies which are similar to the graft-versus-leukemia activity that is well documented in human hematological malignancies. Renal cell carcinoma has been shown to be responsive to immunotherapy with recombinant human cytokines and may be an ideal model for exploring this novel therapy. Clinical investigations have demonstrated regression of metastatic renal cell carcinoma occurs in some patients following nonablative allogeneic HCT. However, graft-versus-host disease remains a significant toxicity of nonablative transplantation, and further investigations are warranted to further evaluate this promising approach and to improve its safety.

Original languageEnglish
Pages (from-to)805-812
Number of pages8
JournalBone Marrow Transplantation
Volume30
Issue number12
DOIs
StatePublished - Dec 2002

Fingerprint

Cell Transplantation
Renal Cell Carcinoma
Transplants
Graft vs Host Disease
Hematologic Neoplasms
Immunotherapy
Neoplasms
Leukemia
Therapeutics
Transplantation
Cytokines
Safety

Keywords

  • Hematopoietic cell transplantation
  • Nonmyeloablative
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

@article{eba6921b75f14b8196754ab4e20d54d7,
title = "Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma",
abstract = "Nonablative hematopoietic cell transplantation (HCT) is becoming a preferred treatment for those recipients in whom the potential toxicity risk of standard ablative allogeneic therapy may be unacceptable. Graft-versus-malignancy effects may be generated against epithelial malignancies which are similar to the graft-versus-leukemia activity that is well documented in human hematological malignancies. Renal cell carcinoma has been shown to be responsive to immunotherapy with recombinant human cytokines and may be an ideal model for exploring this novel therapy. Clinical investigations have demonstrated regression of metastatic renal cell carcinoma occurs in some patients following nonablative allogeneic HCT. However, graft-versus-host disease remains a significant toxicity of nonablative transplantation, and further investigations are warranted to further evaluate this promising approach and to improve its safety.",
keywords = "Hematopoietic cell transplantation, Nonmyeloablative, Renal cell carcinoma",
author = "Robert Nelson and Theodore Logan and Rafat Abonour",
year = "2002",
month = "12",
doi = "10.1038/sj.bmt.1703740",
language = "English",
volume = "30",
pages = "805--812",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma

AU - Nelson, Robert

AU - Logan, Theodore

AU - Abonour, Rafat

PY - 2002/12

Y1 - 2002/12

N2 - Nonablative hematopoietic cell transplantation (HCT) is becoming a preferred treatment for those recipients in whom the potential toxicity risk of standard ablative allogeneic therapy may be unacceptable. Graft-versus-malignancy effects may be generated against epithelial malignancies which are similar to the graft-versus-leukemia activity that is well documented in human hematological malignancies. Renal cell carcinoma has been shown to be responsive to immunotherapy with recombinant human cytokines and may be an ideal model for exploring this novel therapy. Clinical investigations have demonstrated regression of metastatic renal cell carcinoma occurs in some patients following nonablative allogeneic HCT. However, graft-versus-host disease remains a significant toxicity of nonablative transplantation, and further investigations are warranted to further evaluate this promising approach and to improve its safety.

AB - Nonablative hematopoietic cell transplantation (HCT) is becoming a preferred treatment for those recipients in whom the potential toxicity risk of standard ablative allogeneic therapy may be unacceptable. Graft-versus-malignancy effects may be generated against epithelial malignancies which are similar to the graft-versus-leukemia activity that is well documented in human hematological malignancies. Renal cell carcinoma has been shown to be responsive to immunotherapy with recombinant human cytokines and may be an ideal model for exploring this novel therapy. Clinical investigations have demonstrated regression of metastatic renal cell carcinoma occurs in some patients following nonablative allogeneic HCT. However, graft-versus-host disease remains a significant toxicity of nonablative transplantation, and further investigations are warranted to further evaluate this promising approach and to improve its safety.

KW - Hematopoietic cell transplantation

KW - Nonmyeloablative

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0036947850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036947850&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1703740

DO - 10.1038/sj.bmt.1703740

M3 - Article

C2 - 12476272

AN - SCOPUS:0036947850

VL - 30

SP - 805

EP - 812

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -